Aravive, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Fredric N. Eshelman
- Full Time Employees
- 23
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- River Oaks Tower Houston TX United States of America 77098
- IPO Date
- Mar 21, 2014
- CIK
- 0001513818
- Website
- aravive.com
- Similar Companies
- Business
- Aravive, Inc. (ARAV) is a clinical-stage biopharmaceutical company that develops targeted therapies inhibiting the GAS6-AXL signaling pathway to treat life-threatening diseases including solid tumors and fibrosis. The company focuses on its lead product candidate batiraxcept (formerly AVB-500), an ultrahigh-affinity decoy protein designed to capture GAS6 and block AXL receptor signaling, thereby inhibiting cancer cell survival, metastasis, and resistance to standard therapies; batiraxcept has advanced in clinical trials for platinum-resistant recurrent ovarian cancer (Phase 3), clear cell renal cell carcinoma (Phase 1b/2), and pancreatic adenocarcinoma (Phase 1b), with earlier evaluation in combination with agents such as durvalumab. Founded in 2007 as a private entity and publicly listed following a 2018 merger with Versartis, Inc., which included a name change and 1-for-6 reverse stock split, Aravive maintains headquarters in Houston, Texas, and previously conducted operations primarily in the United States across North America and Europe trial sites. In recent developments, Aravive announced in January 2024 its intent to delist from Nasdaq and liquidate assets after terminating all clinical trials, marking a significant wind-down of operations; earlier changes included a $41.5 million private placement financing in October 2022 with investors such as BVF Partners and Eshelman Ventures to fund Phase 3 ovarian cancer readout and expansion into renal and pancreatic indications, alongside strategic collaborations like one with 3D Medicines for AVB-500 commercialization in Greater China receiving a $12 million upfront payment.
Kratos' Aegis Readiness Assessment Vehicle Type B (ARAV-B) Medium-Range Ballistic Missile Target Successfully Engaged, Intercepted by U.S. Guided Missile Destroyers USS Bulkeley (DDG-84) and USS Thomas Hudner (DDG-116) Using Standard Missile 3 (SM-3)
Why Is Aravive (ARAV) Stock Down 52% Today?
Aravive stock slumps on Nasdaq delisting plan, dissolution
Aravive, Inc. to Delist from The Nasdaq Stock Market
Penny Stocks To Buy? Watch These 3 Under $5 Before Next Week
Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
Why Is Aravive (ARAV) Stock Down 58% Today?
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023
Aravive to Participate in William Blair's Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023
3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally
Aravive To Participate in the Jefferies Global Healthcare Conference
Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023
7 Short-Interest Stocks to Target for Explosive Gains
What Makes Aravive (ARAV) a New Buy Stock
7 Short-Squeeze Stocks That Are Driving Hedge Funds Crazy
7 Short-Squeeze Stocks That Could Explode in April
Aravive (ARAV) Reports Q4 Loss, Tops Revenue Estimates
MDA Breakout Stocks Week 9 - March 2023: High-Frequency Gainers To Give You An Edge